Tony Butler News
-
Merck & Co., Bristol-Myers Squibb Co. and Roche Holding AG have opened a new front against cancer with the next generation of experimental drugs that use the human immune system to seek and destroy tumor cells.
-
Johnson & Johnson, the world’s largest seller of health-care products, won approval for the first in a new family of diabetes drugs, giving them the edge against rivals developing similar medicines.
-
With two Alzheimer’s drugs in the final stage of human testing and two more being developed behind them, Eli Lilly & Co. is committed to one of the riskiest bets in medicine to fill a potential $10 billion revenue gap .
-
Merck & Co., facing generic competition in August to its top-selling asthma drug Singulair, reported second-quarter profit that beat analyst estimates on higher sales of the diabetes medicines Januvia and Janumet.
-
Pfizer Inc., the world’s largest drugmaker, put in place the last piece of its plan to refocus the company on developing new drugs, announcing it would start the separation of its animal-health business this month.
-
The elite Pentagon research unit that helped create the Internet and stealth fighter jets is now taking on diarrhea.
-
With the worst flu outbreak since 2009 gripping the U.S., vaccine makers are determined to do better next season. They’re developing powerful vaccines that hold the promise of cutting incidences of flu by the thousands.
-
Ian Read , the new chief executive officer of Pfizer Inc. , plans to lower costs by closing labs and reducing research spending by as much as $3 billion as the company faces declining sales of its best-selling drug.
-
Health plans will pay for expanded use of Merck & Co.’s Gardasil vaccine after a U.S. panel recommended it be given to boys to reduce transmission of a virus that causes cervical cancer, insurance executives said.
-
Eli Lilly & Co. said costs for Barack Obama’s health-care law were 12 times higher than one analyst estimated. That result may be the first of such surprises from pharmaceutical companies this earnings season.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page